Navigation Links
Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol

Researchers at The University of Texas M. D. Anderson Cancer Center have developed a way to test whether the new targeted therapy Tarceva and the widely used chemotherapy drug Taxol are effectively killing tumor cells. They say that with further refinement, the test may make it possible to accurately assess whether patients are responding to these agents, as well as potentially others, within days of beginning therapy.

In two different studies being presented at the annual meeting of the American Association for Cancer Research (AACR), the research team will describe how the test measures the activity of several members of the cyclin-dependent kinase (CDK) family of enzymes, which are the triggering molecules that allow a cell to grow and divide. CDK cell cycle enzymes are the end target of numerous cellular pathways that are involved in cancer development and progression, the researchers say.

Before these studies, no one has been able to accurately test the function of enzymes from a tumor sample, says Naoto Ueno, M.D., Ph.D., an associate professor in the Breast Cancer Translational Research Laboratory and the Department of Blood and Marrow Transplantation.

"Testing CDK only has been possible by measuring gene expression, but our industry collaborator has provided a way that lets us test real enzyme activity within a human tumor sample," he says. "Our hope is to be able to use this system as a molecular marker to assess whether an anti-cancer therapy is working."

ABSTRACT # 1670

Sensitivity to Tarceva Depends on CDK2

In the first study, M. D. Anderson researchers found that loss of the CDK2 enzyme strongly correlated with a cancer's sensitivity to Tarceva.

That means testing activity of CDK2, the enzyme that drives cell division, can reveal whether or not a tumor will respond to Tarceva, says Naoto Ueno, M.D., Ph.D., an associate professor in the Breast Cancer Translational Research Laboratory and the Departm
'"/>

Source:University Of Texas M. D. Anderson Cancer Center


Page: 1 2 3

Related biology news :

1. Measuring the impact of post-genomics on Mediterranean populations
2. Measuring hormone cuts antibiotic use in half in pneumonia patients
3. Measuring hidden parasites in falciparum malaria
4. Measuring artery repair cells could become new heart disease test
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Jump-starting T Cells In Skin Cancer
7. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
8. Fox Chase Cancer Center scientists identify immune-system mutation
9. Breakthrough Microarray-based Technology for the Study of Cancer
10. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
11. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery

Post Your Comments:
(Date:11/24/2009)...utes fish food is a matter of debate. A high-profi...lmost 50 percent of their carbon from trees and le...errestrial and aquatic ecosystems. , But new res... is not likely to be true. Algae provide a much ri...ng to research published this week in the Proceed...
(Date:11/24/2009)... is available in Spanish . , The presence o...of inflammatory substances in the blood, hinders t...y a research project of the University of Navarra ... at the School of Pharmacy. , The project, entit...tion to the control of body weight and inflammatio...
(Date:11/23/2009)....C. The community-associated strain of the deadly...ant to most common antibioticsposes a far greater ...its way into hospitals, according to a study in th.... , The new threat is easily picked up in fitne...as increased the overall burden of MRSA within hos...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2New study finds MRSA on the rise in hospital outpatients 2Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 1Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 2Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 3Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 51880 1Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 51880 2Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 51880 3Supelco 28R 29 and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 13058 1Supelco 28R 29 and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 13058 2Supelco 28R 29 and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 13058 3
...bruary 22, 2009--Researchers at the Dana-Farber Ca...r Medical Research (Burnham) and the Centers for D...the identification of human monoclonal antibodies ...fluenza A viruses, including avian influenza A (H5...d some seasonal influenza viruses. These antibodie...
...L, N.J., Feb. 18 BIO-key International, Inc. (OTC...lease fourth quarter 2008 financial results on Tue...In conjunction with the release, BIO-key has sched...ve over the Internet on Tuesday, February 24, 2009... BIO-key International, Inc. Fourth Quarter 2...
...e quick decline of a tiny shrimp-like species, kno... aggressive population growth of non-native quagga...As invasive mussel numbers increase, food sources ...ily and unilaterally declined. , A recent researc...ratory published,this week in Freshwater Biology ...
Other Biology News:Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 2Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 3BIO-key(R) Announces Fourth Quarter and 2008 Year-End Earnings Release and Conference Call Schedule 2
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PR...aq: DCGN ) today announced the approval of all of ...rt for the District of Delaware,(the "Bankruptcy C...n for,relief under Chapter 11 of the United States... The orders issued by the Bankruptcy Court all...
(Date:11/24/2009)..., SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall...ceutical company focused on developing and commerc...d today that Anthony DiTonno, President and Chief ...21st Annual Piper Jaffray Health Care Conference, ...ce Hotel in New York, New York. ,, Mr. DiTonno...
(Date:11/24/2009)...ATTLE, Nov. 24 Blue Marble Energy ...ssa Public Development Authority (OPDA) were recen...nity Economic Revitalization Board (CERB) in a pri...irst specialty biochemical biorefinery in Lincoln ...antly speed the development of our biorefinery and...
(Date:11/24/2009)... Primary efficacy endpoint has been met for pat...rial cancer, , QUEBEC CITY, Nov. 24 /PRNewswi...ZS ; TSX: AEZ) (the "Company"), a global biopharma...oncology, today announced positive efficacy data f...ptide conjugate, AEZS-108 (formerly AN-152), in pa...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
.../Xinhua-PRNewswire-FirstCall/ --,China Biologic Pr... "the,Company"), one of the leading plasma-based p...f China ("PRC"), today announced that the Company,...Drug Administration,("SFDA") (1) to start the prod...od product prepared from plasma and (2) to commenc...
...PRNewswire/ -- Today, Tigermed,Consulting Ltd. joi...in,their CRO Service Alliance CROSA that provides ...nies. Tigermed,s expertise in clinical,development...aceutical,development capabilities of the alliance...Sciences entered into a,CRO Service Alliance in Ma...
...FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ...cused on,endocrine therapy and oncology, today ann..., Chairman and CEO of Andros Men,s Health Institut...er Presentation in a Poster,Session at the 23rd An...h,was held March 26-28, 2008 in Milan, Italy. Titl...
Other Biology Technology:China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 2China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 3Shanghai CRO Service Alliance Adds Clinical Development Capabilities 2Shanghai CRO Service Alliance Adds Clinical Development Capabilities 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6
...y modifications to the original formulas in effort...till play an important role in tissue,culture. A s...and osmotic balance in the medium and to provide t...is as valuable today as when it was first develope...
...ilizes hands-off homogenization through a vortex a...without hand grinding; eliminating the need to cle... - Includes tough customized tubes to bead beat an...rmat - Compatible with vortexes, MO BIOs Precellys...
Ellman's Reagent from Cayman Chemical
... spectrometer enables high-throughput solutions fo...LXQ linear ion trap mass spectrometer is designed ...ivering the fast cycle time and increased sensitiv...rice. The combination of fast cycle time and high...
Biology Products: